Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NASDAQ:INSM NASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$10.11-0.8%$11.43$5.90▼$14.51$657.43M1.79784,757 shs593,968 shsINSMInsmed$101.17-3.6%$145.87$64.85▼$212.75$22.66B0.892.29 million shs8.59 million shsPCRXPacira BioSciences$23.15-2.1%$23.36$18.80▼$27.64$930.18M0.32591,890 shs513,960 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas0.00%+2.93%-9.10%-24.41%+53.58%INSMInsmed0.00%-22.72%-34.23%-29.70%+54.30%PCRXPacira BioSciences0.00%-7.26%+1.68%+12.57%-6.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$10.11-0.8%$11.43$5.90▼$14.51$657.43M1.79784,757 shs593,968 shsINSMInsmed$101.17-3.6%$145.87$64.85▼$212.75$22.66B0.892.29 million shs8.59 million shsPCRXPacira BioSciences$23.15-2.1%$23.36$18.80▼$27.64$930.18M0.32591,890 shs513,960 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas0.00%+2.93%-9.10%-24.41%+53.58%INSMInsmed0.00%-22.72%-34.23%-29.70%+54.30%PCRXPacira BioSciences0.00%-7.26%+1.68%+12.57%-6.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.40Hold$14.8646.95% UpsideINSMInsmed 3.00Buy$211.86109.41% UpsidePCRXPacira BioSciences 2.29Hold$29.4027.00% UpsideCurrent Analyst Ratings BreakdownLatest INSM, PCRX, and ARVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026INSMInsmed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/8/2026INSMInsmed GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$230.00 ➝ $226.005/8/2026INSMInsmed Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$220.00 ➝ $205.005/8/2026INSMInsmed Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$177.00 ➝ $160.005/4/2026ARVNArvinas CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $24.005/1/2026PCRXPacira BioSciences Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$22.00 ➝ $24.005/1/2026PCRXPacira BioSciences Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $32.004/27/2026ARVNArvinas Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/21/2026INSMInsmed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026INSMInsmed Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$212.004/16/2026INSMInsmed GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$230.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$262.60M2.48N/AN/A$6.76 per share1.50INSMInsmed$606.42M36.01N/AN/A$3.46 per share29.24PCRXPacira BioSciences$726.41M1.25$3.78 per share6.13$16.62 per share1.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$80.80M-$1.28N/AN/AN/A-30.77%-14.25%-9.31%5/12/2026 (Estimated)INSMInsmed-$1.28B-$6.41N/A72.79N/A-144.44%-121.03%-49.98%N/APCRXPacira BioSciences$7.03M$0.12192.939.85N/A0.70%10.24%5.47%N/ALatest INSM, PCRX, and ARVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ARVNArvinas-$0.95N/AN/AN/A$16.61 millionN/A5/7/2026Q1 2026INSMInsmed-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million4/30/2026Q1 2026PCRXPacira BioSciences$0.61$0.60-$0.01$0.07$171.80 million$177.38 million2/26/2026Q4 2025PCRXPacira BioSciences$0.85$0.57-$0.28$0.04$201.93 million$196.87 million2/24/2026Q4 2025ARVNArvinas-$0.55-$1.10-$0.55-$1.10$37.26 million$9.50 million2/19/2026Q4 2025INSMInsmed-$1.07-$1.54-$0.47-$1.54$263.97 million$263.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.924.92INSMInsmed0.763.833.54PCRXPacira BioSciences0.564.733.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%INSMInsmedN/APCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipARVNArvinas4.73%INSMInsmed2.10%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42064.52 million61.47 millionOptionableINSMInsmed1,664215.85 million211.32 millionOptionablePCRXPacira BioSciences72039.35 million36.83 millionOptionableINSM, PCRX, and ARVN HeadlinesRecent News About These CompaniesPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8 at 8:00 AM | globenewswire.comPacira BioSciences Mails Letter to StockholdersMay 5, 2026 | globenewswire.comComparing Pacira BioSciences (NASDAQ:PCRX) & Hoth Therapeutics (NASDAQ:HOTH)May 5, 2026 | americanbankingnews.comAssessing Pacira BioSciences (PCRX) Valuation After Earnings Update And New EXPAREL Real World DataMay 3, 2026 | uk.finance.yahoo.comUniversal Beteiligungs und Servicegesellschaft mbH Boosts Stock Position in Pacira BioSciences, Inc. $PCRXMay 2, 2026 | marketbeat.comPharmaCorp Completes Acquisition of Pharmacy Files in Western CanadaMay 1, 2026 | globenewswire.comRoyal Bank Of Canada Issues Positive Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock PriceMay 1, 2026 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Shares Gap Up Following Analyst UpgradeMay 1, 2026 | marketbeat.comNeedham & Company LLC Raises Pacira BioSciences (NASDAQ:PCRX) Price Target to $32.00May 1, 2026 | marketbeat.comPacira BioSciences Inc (PCRX) Q1 2026 Earnings Call Highlights: Strong Product Growth Amidst ...May 1, 2026 | finance.yahoo.comPacira outlines 2026 revenue guidance of $745M-$770M while advancing PCRX-201 Phase II milestonesMay 1, 2026 | seekingalpha.comPacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comPacira BioSciences (NASDAQ:PCRX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPSApril 30, 2026 | marketbeat.comPacira BioSciences Q1 Earnings Call HighlightsApril 30, 2026 | marketbeat.comPacira BioSciences, Inc. 2026 Q1 - Results - Earnings Call PresentationApril 30, 2026 | seekingalpha.comPacira BioSciences Reports First Quarter 2026 Financial ResultsApril 30, 2026 | globenewswire.comPharmaCorp to Acquire Eight Pharmacies and Provides Acquisition Pipeline UpdateApril 30, 2026 | globenewswire.comPharmaCorp Announces Fourth Quarter and Fiscal Year 2025 Financial ResultsApril 29, 2026 | globenewswire.comPacira BioSciences Files Definitive Proxy Materials and Mails Letter to ShareholdersApril 28, 2026 | globenewswire.comDo options traders know something about Pacira BioSciences stock we don't?April 27, 2026 | msn.comReal-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip ArthroplastyApril 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINSM, PCRX, and ARVN Company DescriptionsArvinas NASDAQ:ARVN$10.11 -0.08 (-0.79%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$10.01 -0.10 (-0.98%) As of 05/8/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Insmed NASDAQ:INSM$101.17 -3.83 (-3.65%) Closing price 05/8/2026 03:59 PM EasternExtended Trading$102.08 +0.91 (+0.90%) As of 05/8/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Pacira BioSciences NASDAQ:PCRX$23.15 -0.49 (-2.07%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$23.18 +0.04 (+0.15%) As of 05/8/2026 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
